Phase II trial of a 75‐mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non‐small cell lung cancer

Cancer

Volumn 75, Issue 4, 1995, Pages 968-972

  Miller, Vincent A ^a   Rigas, James R ^a   Francis, Prudence A ^a   Grant, Stefan C ^a   Pisters, Katherine M W ^a   Kris, Mark G ^a   Woolley, Karen ^a   Venkatraman, Ennapadam S ^a   Heelan, Robert T ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

docetaxel; NSCLC; taxoid; taxotere

Indexed keywords

CIMETIDINE; DIPHENHYDRAMINE; DOCETAXEL; PACLITAXEL; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG MECHANISM; FEMALE; FEVER; FLUSHING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; DRUG THERAPY, COMBINATION; FEMALE; HUMAN; LUNG NEOPLASMS; MALE; MIDDLE AGE; NEUTROPENIA; PACLITAXEL; PREDNISONE; PREMEDICATION; SUPPORT, NON-U.S. GOV'T; SURVIVAL RATE;

EID: 0028896128     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19950215)75:4<968::AID-CNCR2820750411>3.0.CO;2-Y     Document Type: Article

References (18)

1. Phase II trial of docetaxel (taxotere) in patients with stage III and IV non‐small cell lung cancer
2. A highly efficient, practical approach to natural taxol
3. Application of the vicinal oxyamination reaction with asymmetric induction to the hemisynthesis of taxol and analogues
4. Promotion of microtubule assembly in vitro by taxol
5. Relationships between the structure of taxol analogues and their antimitotic activity
6. Effects of taxol on cell growth and in vitro microtubule assembly
7. Taxotere is an active drug in non‐small cell lung (NSCLC) cancer: a phase II trial of the early clinical trials group (ECTG)
8. Phase II trial of taxotere in patients with non‐small cell lung cancer
9. A new international staging system for lung cancer
10. Evaluation of response criteria in advanced lung cancer
11. Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non‐small cell lung cancer, with an analysis of methods of response assessment
12. Measurable or evaluable disease: does it matter?
13. Pretreatment with corticosteroids to alleviate reactions to intravenous contrast material
14. Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies
15. Quality of life assessment in individuals with lung cancer: testing the lung cancer symptom scale (LCSS)
16. Second EORTC‐clinical screening group (CSG) phase II trial of taxotere (docetaxel) as first line chemotherapy in advanced breast cancer (ABC)
17. Phase II trial of docetaxel in previously untreated non‐small cell lung cancer (NSCLC)
18. Docetaxel (taxotere) toxicities: analysis of a single institution experience of 168 patients (623 courses)